{"id":44480,"date":"2022-05-31T07:01:46","date_gmt":"2022-05-31T05:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/"},"modified":"2022-05-31T07:01:46","modified_gmt":"2022-05-31T05:01:46","slug":"element-nutritional-sciences-reports-q1-2022-financial-performance","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/","title":{"rendered":"Element Nutritional Sciences Reports Q1 2022 Financial Performance"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nRealized revenue growth of $2.3 million in Q1 2022, an increase of 559% versus Q1 2021, with a gross margin of 40%\n<\/li>\n<li>\nExpanded distribution through partnership with large retailers and brand accelerators including Publix, Pattern, Sam\u2019s Club, and Walgreens\n<\/li>\n<li>\nInnovation pipeline now includes JAKTRX\u2122 PROMINO, and Rejuvenate\u2122 Muscle Activator, targeting high potential nutrition and consumer markets such as sports nutrition, orthopaedics, immune health and oncology\n<\/li>\n<\/ul>\n<p>BURLINGTON, Ontario&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Felmtinc.com%2Foverview%2Fdefault.aspx&amp;esheet=52734625&amp;newsitemid=20220530005440&amp;lan=en-US&amp;anchor=Element+Nutritional+Sciences+Inc.&amp;index=1&amp;md5=65e8b7598f1cde60c9e0684ac2587d1d\" rel=\"nofollow noopener\" shape=\"rect\">Element Nutritional Sciences Inc.<\/a> (CSE:ELMT; OTC:ELNSF; FRANKFURT:93X) (the \u201cCompany\u201d or \u201cElement\u201d), today reports its financial results for the three months ended March 31, 2022 (\u201cQ1 2022\u201d). All amounts are expressed in Canadian dollars.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/5\/ens_logo_web.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/21\/ens_logo_web.jpg\"><\/a><\/p>\n<p>\n<b>Stuart Lowther, Chief Executive Officer of Element <\/b>commented, \u201cElement delivered outstanding results in Q1 2022. We started the year with a milestone quarter highlighted by record revenues of $2.3 million, demonstrating a year-over-year growth of 559%. These results are attributable to our commitment to execute on our strategic plan, significant cost discipline and continued focus on expanding our diversified distribution pipeline, especially in the U.S. With significant retail and e-commerce partnerships in place, an improved balance sheet supported by our recent financing, and clinically-proven and patented products in the pipeline catering to high potential global nutrition and consumer markets, we believe Element is well positioned for success in 2022 and beyond.\u201d\n<\/p>\n<p>\n<b>Highlights during and subsequent to Q1 2022<\/b>\n<\/p>\n<p>\n<i>Financial<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nGenerated revenue of $2.3 million, up 559% from $0.3 million in Q1 2021\n<\/li>\n<li>\nIncreased gross margin to 40% in Q1 2022\n<\/li>\n<li>\nImproved operating income to $(0.8) million and net income to $(1.0) million\n<\/li>\n<li>\nAnnounced and closed its short form prospectus offering raising gross proceeds of $3.5 million.\n<\/li>\n<\/ul>\n<p>\n<i>Distribution<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nExpanded its distribution footprint and entered the U.S. grocery channel with Publix Super Markets Inc. (\u201cPublix\u201d). Rejuvenate\u2122 is now on shelves at 1,295 Publix grocery stores across the U.S.\n<\/li>\n<li>\nAnnounced that its flagship Rejuvenate\u2122 product was available online at Walgreens and across all Sam\u2019s Club locations across the U.S.\n<\/li>\n<li>\nSecured automatic warehouse replenishment for its Rejuvenate\u2122 ready to drink plant protein beverage at Sam\u2019s Club, following Sam\u2019s Club achieving full sell through of its first purchase order\n<\/li>\n<li>\nAccelerated sales on the Amazon platform through a partnership with Pattern Inc. (\u201cPattern\u201d), the third largest global supplier to Amazon\n<\/li>\n<li>\nIntegrated its industry-leading JAKTRX\u2122 performance supplement branded products on Amazon.com, through its partnership with Pattern in addition to on the Company\u2019s direct to consumer e-commerce platform, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.JAKTRX.com&amp;esheet=52734625&amp;newsitemid=20220530005440&amp;lan=en-US&amp;anchor=www.JAKTRX.com&amp;index=2&amp;md5=537ee3d4fd57463fb53e103c4803e7cb\" rel=\"nofollow noopener\" shape=\"rect\">www.JAKTRX.com<\/a>\n<\/li>\n<li>\nNew and patented Promino\u2122 line of sports nutrition products is also available on Amazon with sales and fulfillment facilitated through Pattern\n<\/li>\n<li>\nAnnounced that its industry-leading JAKTRX\u2122 performance supplement branded products as well as its new patented Promino\u2122 line of sports nutrition products are now available to customers across the United States on the Company\u2019s e-commerce platform, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.JAKTRX.com&amp;esheet=52734625&amp;newsitemid=20220530005440&amp;lan=en-US&amp;anchor=www.JAKTRX.com&amp;index=3&amp;md5=8ad02626c4ed12cbb0fc1db7606eb023\" rel=\"nofollow noopener\" shape=\"rect\">www.JAKTRX.com<\/a>\n<\/li>\n<\/ul>\n<p>\n<i>Innovation<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAcquired the right to use the same plant-based amino acid formulation underlying its Rejuvenate\u2122 muscle health products to develop a new higher dosage formulation for the sports nutrition market, with JAKTRX\u2122 Promino as the first product to be launched under the higher dosage formulation\n<\/li>\n<li>\nAnnounced that the clinically proven amino acid formulation used in Rejuvenate\u2122 muscle health products received a global Patent Cooperation Treaty patent issued by the United States Patent and Trademark Office, extending Element\u2019s intellectual property protection beyond the United States into foreign markets including, but not limited to, Canada, the European Union and the Asia Pacific countries\n<\/li>\n<li>\nRecently announced that it has completed production trials for its all new Rejuvenate\u2122 Muscle Activator product, which is expected to launch online and through the Company\u2019s established pharmacy and grocery retail network in the United States, in the third quarter of 2022\n<\/li>\n<\/ul>\n<p>\n<i>Corporate<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCommenced trading on the OTCQB\u00ae Venture Market (OTCQB) under the symbol \u201cELNSF\u201d on February 2, 2022\n<\/li>\n<\/ul>\n<p>\n<b>Financial Results<\/b>\n<\/p>\n<p>\nIn Q1 2022, Element generated revenue of $2.3 million, up 559% from $0.3 million in Q1 2021. Results are attributable to new listings with large retailers, as well as increased e-commerce sales and sales to existing retailers for the Company\u2019s flagship Rejuvenate\u2122 product.\n<\/p>\n<p>\nElement reported a net loss of $1.0 million in Q1 2022, as compared to a net loss of $1.5 million in Q1 2021. The impact of the increased revenue and gross profit was offset in part by the issuance of warrants and options to key personnel and onboarding new staff, and professional fees related to investor relations activities.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n(expressed in thousands of Canadian dollars)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nFor the 3 months<br \/>\n<br \/>ended, March 31,\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nFor the 3 months<br \/>\n<br \/>ended, March 31,\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n(unaudited)\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n(unaudited)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>2022<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRevenue\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,279\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n346\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCost of sales\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,373\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n345\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>905<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>1<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Operating Expenses<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSalaries and wages\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n752\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n724\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAdvertising and marketing\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n216\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n203\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGeneral and administrative\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n221\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n43\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDepreciation\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n7\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n19\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nProfessional fees\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n569\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n472\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct development\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total operating expenses<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>1,768<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>1,463<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Loss before other income (expenses)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(863)<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(1,462)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Other Income (Loss) and (expenses):<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nForeign exchange (loss) gain\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(56)\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n46\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nInterest expense\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(28)\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(6)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBank charges &amp; interest\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(29)\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(10)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther Income\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Net Loss<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(976)<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(1,429)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Readers are encouraged to review the Company\u2019s complete Q1 2022 financial statements and management\u2019s discussion and analysis thereof for a fulsome assessment of the Company\u2019s performance and applicable risk factors, available at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=52734625&amp;newsitemid=20220530005440&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=4&amp;md5=de95e2bb9a0faff6e1a989b1645eee2f\" rel=\"nofollow noopener\" shape=\"rect\">www.sedar.com<\/a>.<\/b>\n<\/p>\n<p>\n<b>About Element<\/b>\n<\/p>\n<p>\nElement is an innovative and research driven Canadian nutraceutical company specializing in the development of patented and science-based products for the global consumer packaged goods market, with a portfolio focused specifically on men and women over the age of 40. Element\u2019s lead product, Rejuvenate\u2122, is a proprietary formulation that is clinically proven to assist in the rebuilding, restoration and rejuvenation of natural loss of muscle mass due to aging or other medical conditions. Element also offers JAKTRX\u2122, an elite brand of performance supplements. Element was founded in 2015 and is located in Burlington, Ontario.\n<\/p>\n<p>\nTo learn more about Element, visit elmtinc.com.\n<\/p>\n<p>\nMore information about <b><i>Rejuvenate<\/i><i>\u2122<\/i><i> <\/i><\/b>can be found at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rejuvenatemuscle.com&amp;esheet=52734625&amp;newsitemid=20220530005440&amp;lan=en-US&amp;anchor=www.rejuvenatemuscle.com&amp;index=5&amp;md5=09544aff9c213fe74602d2d520d8b161\" rel=\"nofollow noopener\" shape=\"rect\">www.rejuvenatemuscle.com<\/a>\n<\/p>\n<p>\nMore information about <b><i>JAKTRX\u2122 and Promino\u2122 <\/i><\/b>can be found at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.jaktrx.com&amp;esheet=52734625&amp;newsitemid=20220530005440&amp;lan=en-US&amp;anchor=www.jaktrx.com&amp;index=6&amp;md5=e5d7bd52539b6d34f78099bd00d86109\" rel=\"nofollow noopener\" shape=\"rect\">www.jaktrx.com<\/a>\n<\/p>\n<p>\n<b>Forward Looking Statements<\/b>\n<\/p>\n<p>\nThis news release contains &#8220;forward-looking information&#8221; and &#8220;forward-looking statements&#8221; (collectively, &#8220;forward looking statements&#8221;) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as \u201cexpects\u201d, or \u201cdoes not expect\u201d, \u201cis expected\u201d, \u201canticipates\u201d or \u201cdoes not anticipate\u201d, \u201cplans\u201d, \u201cbudget\u201d, \u201cscheduled\u201d, \u201cforecasts\u201d, \u201cestimates\u201d, \u201cbelieves\u201d or \u201cintends\u201d or variations of such words and phrases or stating that certain actions, events or results \u201cmay\u201d or \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d or \u201cwill\u201d be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward looking statements in this news release include: the anticipated launch of the Rejuvenate\u2122 Muscle Activator product in Q3 2022, and the future performance of the Company.\n<\/p>\n<p>\nThese forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; expectations regarding the size of the United States and Canadian health, nutraceutical and wellness markets and changing consumer habits; the viability of the Company\u2019s products; availability of distribution channels for the Company\u2019s product offerings; the ability of the Company to successfully achieve its business objectives; plans for expansion; successful development of the Company\u2019s proposed products; the presence of laws and regulations that may impose restrictions or recalls on the sale of the Company\u2019s products in the United States and Canada; customer and distributor relations; fluctuations in securities markets; and the inability of the Company to obtain adequate insurance to cover risks and hazards. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.\n<\/p>\n<p>\nNo stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nStuart Lowther<br \/>\n<br \/>Chairman, CEO and President<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x69;r&#64;&#x65;l&#101;&#x6d;&#101;&#x6e;&#x74;&#110;&#x75;&#x74;&#114;&#x69;t&#105;&#x6f;n&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x72;&#64;&#101;l&#x65;&#x6d;&#x65;&#110;&#116;n&#x75;&#x74;&#x72;&#105;&#116;i&#x6f;&#x6e;&#x2e;&#99;&#111;m<\/a><br \/>416-467-5229\n<\/p>\n<p>\nMarc Charbin<br \/>\n<br \/>Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;&#111;&#x3a;i&#114;&#x40;e&#x6c;&#x65;&#109;&#x65;n&#116;&#x6e;u&#x74;&#x72;&#105;&#x74;i&#111;&#x6e;&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x72;&#x40;&#x65;&#x6c;&#x65;&#x6d;&#101;&#110;&#116;&#110;&#117;trit&#x69;&#x6f;&#x6e;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>416-467-5229\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Realized revenue growth of $2.3 million in Q1 2022, an increase of 559% versus Q1 2021, with a gross margin of 40% Expanded distribution through partnership with large retailers and brand accelerators including Publix, Pattern, Sam\u2019s Club, and Walgreens Innovation pipeline now includes JAKTRX\u2122 PROMINO, and Rejuvenate\u2122 Muscle Activator, targeting high potential nutrition and consumer &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44480","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Element Nutritional Sciences Reports Q1 2022 Financial Performance - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Element Nutritional Sciences Reports Q1 2022 Financial Performance - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Realized revenue growth of $2.3 million in Q1 2022, an increase of 559% versus Q1 2021, with a gross margin of 40% Expanded distribution through partnership with large retailers and brand accelerators including Publix, Pattern, Sam\u2019s Club, and Walgreens Innovation pipeline now includes JAKTRX\u2122 PROMINO, and Rejuvenate\u2122 Muscle Activator, targeting high potential nutrition and consumer ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-31T05:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/21\/ens_logo_web.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Element Nutritional Sciences Reports Q1 2022 Financial Performance\",\"datePublished\":\"2022-05-31T05:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/\"},\"wordCount\":1427,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220530005440\\\/en\\\/1470747\\\/21\\\/ens_logo_web.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/\",\"name\":\"Element Nutritional Sciences Reports Q1 2022 Financial Performance - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220530005440\\\/en\\\/1470747\\\/21\\\/ens_logo_web.jpg\",\"datePublished\":\"2022-05-31T05:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220530005440\\\/en\\\/1470747\\\/21\\\/ens_logo_web.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220530005440\\\/en\\\/1470747\\\/21\\\/ens_logo_web.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/element-nutritional-sciences-reports-q1-2022-financial-performance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Element Nutritional Sciences Reports Q1 2022 Financial Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Element Nutritional Sciences Reports Q1 2022 Financial Performance - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/","og_locale":"en_US","og_type":"article","og_title":"Element Nutritional Sciences Reports Q1 2022 Financial Performance - Pharma Trend","og_description":"Realized revenue growth of $2.3 million in Q1 2022, an increase of 559% versus Q1 2021, with a gross margin of 40% Expanded distribution through partnership with large retailers and brand accelerators including Publix, Pattern, Sam\u2019s Club, and Walgreens Innovation pipeline now includes JAKTRX\u2122 PROMINO, and Rejuvenate\u2122 Muscle Activator, targeting high potential nutrition and consumer ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-31T05:01:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/21\/ens_logo_web.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Element Nutritional Sciences Reports Q1 2022 Financial Performance","datePublished":"2022-05-31T05:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/"},"wordCount":1427,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/21\/ens_logo_web.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/","url":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/","name":"Element Nutritional Sciences Reports Q1 2022 Financial Performance - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/21\/ens_logo_web.jpg","datePublished":"2022-05-31T05:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/21\/ens_logo_web.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220530005440\/en\/1470747\/21\/ens_logo_web.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/element-nutritional-sciences-reports-q1-2022-financial-performance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Element Nutritional Sciences Reports Q1 2022 Financial Performance"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44480"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44480\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}